(19)
(11) EP 1 527 049 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
29.10.2008 Bulletin 2008/44

(45) Mention of the grant of the patent:
16.07.2008 Bulletin 2008/29

(21) Application number: 03784567.4

(22) Date of filing: 07.08.2003
(51) International Patent Classification (IPC): 
C07D 215/18(2006.01)
(86) International application number:
PCT/JP2003/010054
(87) International publication number:
WO 2004/014860 (19.02.2004 Gazette 2004/08)

(54)

FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS

KONDENSIERTE HETEROZYKLISCHE VERBINDUNGEN ALS PETIDASE INHIBITOREN

COMPOSES HETEROCYCLIQUES FUSIONNES EN TANT QU'INHIBITEURS DE PEPTIDASE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 08.08.2002 JP 2002231950
27.02.2003 JP 2003051575

(43) Date of publication of application:
04.05.2005 Bulletin 2005/18

(73) Proprietor: Takeda Pharmaceutical Company Limited
Osaka-shi, Osaka 541-0045 (JP)

(72) Inventors:
  • OI, Satoru
    Nara-shi, Nara 631-0033 (JP)
  • MAEZAKI, Hironobu
    Toyonaka-shi, Osaka 560-0021 (JP)
  • IKEDOU, Koji
    Himeji-shi, Hyogo 671-0222 (JP)

(74) Representative: Wright, Robert Gordon McRae 
Elkington and Fife LLP, Prospect House, 8 Pembroke Road
Sevenoaks, Kent TN13 1XR
Sevenoaks, Kent TN13 1XR (GB)


(56) References cited: : 
WO-A-98/19998
 WO-A-03/068748
   
  • AUGUSTYNS K ET AL: "THE UNIQUE PROPERTIES OF DIPEPTIDYL-PEPTIDASE IV (DPP IV/CD26) AND THE THERAPEUTIC POTENTIAL OF DPP IV INHIBITORS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 4, 1999, pages 311-327, XP000870290 ISSN: 0929-8673
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).